Skip to content

Fetal Achiral Carboxyterminal Cross-Linked Telopeptide (aCTX) in Serum/Plasma

Published: August 9, 2026Updated: August 16, 2026

This test measures a protein fragment produced during bone remodeling in fetal circulation. It helps assess bone health and development.

Quick summary

["Helps evaluate fetal bone formation and resorption rates during pregnancy."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
11697-0
Short code
Fet Ac arch Vmax sys DOP
Synonyms
Fet Ac arch Vmax sys DOP
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
us-doppler
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your healthcare provider may recommend this test if you’re at risk for complications related to fetal bone development, such as preterm labor, fetal growth restriction, or conditions affecting skeletal development. It may also be used in cases of suspected fetal skeletal dysplasia or other congenital bone disorders.

What to Expect Before the Test

No special preparation is needed. You’ll provide a blood sample, typically drawn from a vein in your arm. The test is usually done during a routine prenatal visit or as part of a specialized fetal assessment.

What the Results Mean

Results are compared to reference ranges for fetal development at your specific gestational age. Elevated levels may indicate increased bone turnover, while lower levels could suggest reduced bone formation. Your provider will interpret results in the context of your pregnancy and medical history.

Common Reasons for Abnormal Results

High levels might suggest conditions like fetal skeletal dysplasia, growth restriction, or preterm labor risks. Low levels could be associated with slower bone development or certain genetic disorders. Always discuss any abnormal results with your healthcare provider.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

This test is primarily used in high-risk pregnancies to monitor fetal skeletal health. It complements other prenatal tests, such as ultrasound or genetic screening, by providing additional data on bone metabolism. Early detection of abnormal bone turnover can help guide interventions to support fetal development.

Short name

Fetal Bone Turnover Marker

Frequently asked questions

What is fetal achiral carboxyterminal cross-linked telopeptide (aCTX)?
aCTX is a protein fragment released during the breakdown and rebuilding of fetal bone. It’s measured in your blood to assess how actively your baby’s bones are forming and breaking down.
Will I need to do anything special before the test?
No special preparation is required. You’ll simply have a blood sample drawn, similar to other routine blood tests.
Can this test detect genetic bone disorders?
While this test can provide information about fetal bone turnover, it’s not a definitive test for genetic bone disorders. It’s often used alongside other prenatal tests, such as ultrasounds or genetic screening, for a comprehensive assessment.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy